#United States #Massachusetts #Breast Cancer #Lumicell #LumiSystem

Lumicell's Innovative LumiSystem™: A New Era in Breast Cancer Surgery

Lumicell, Inc., a pioneer in the field of fluorescence-guided imaging technologies, has made a significant leap in breast cancer treatment with the U.S. launch of its latest innovation, the LumiSystem™. This cutting-edge system is designed to enhance surgical outcomes by providing real-time detection of residual cancer during lumpectomy procedures.

What is LumiSystem™?

LumiSystem™ combines two FDA-approved products: LUMISIGHT™, an optical imaging agent that illuminates suspected cancerous tissues, and the Lumicell Direct Visualization System (DVS), which offers real-time imaging guidance during surgery. Unlike traditional methods that examine removed tissue post-surgery, LumiSystem™ allows surgeons to visibly scan the breast cavity while operating, ensuring that any suspicious areas can be addressed immediately, potentially reducing the need for subsequent surgeries.

As Dr. Irene Wapnir, a professor at Stanford University and an expert in breast surgery, points out, "The limitations of lumpectomy procedures are often echoed in our discussions with patients, particularly regarding the likelihood of needing follow-up surgeries due to positive margins. The LumiSystem™ addresses this concern by enabling us to more effectively identify and excise cancerous tissues during the initial operation, while preserving as much healthy tissue as possible."

Enhanced Surgical Accuracy

With an impressive diagnostic accuracy rate of 84%, LumiSystem™ has demonstrated its efficacy in clinical trials, notably in the INSITE pivotal trial, where it improved surgical outcomes for 10% of patients. This means that cancerous tissues that might have been overlooked by surgeons and pathologists are now being detected and removed more successfully, ultimately offering patients a more reliable treatment option.

Howard Hechler, CEO of Lumicell, emphasizes the significance of this development: "Today marks a milestone for us. With the LumiSystem™ officially available, we are equipping surgeons with a revolutionary tool that detects cancer precisely where it matters — inside the breast cavity in real-time. This launch underscores our dedication to improving surgical precision and patient outcomes."

Implications for Breast-Conserving Surgery

The introduction of LumiSystem™ is poised not only to enhance surgical procedures but also to reshape the way breast-conserving surgeries are approached. By allowing for immediate visual confirmation during surgery, the technology minimizes the chances of leaving residual cancerous cells behind, thereby addressing one of the principal challenges associated with breast cancer surgeries today.

For patients, this innovation can lead to a reduced emotional toll, fewer invasive follow-up surgeries, and a smoother overall treatment journey. Fewer surgeries translate to less time spent recovering and a quicker return to normal life.

For more information about the LumiSystem™ and its groundbreaking features, visit www.LumiSystem.com.

About Lumicell, Inc.

Lumicell, Inc. is a privately held company committed to advancing surgical treatment methods through innovative fluorescence-guided imaging technologies. With a focus on breast cancer, the company is striving to usher in a new standard of care that optimizes surgical outcomes. In addition to the LumiSystem™, Lumicell is exploring other applications of its proprietary optical imaging agent, LUMISIGHT, across various solid tumor types, broadening the scope of their impact on cancer care.

As Lumicell takes this bold step into the future of breast cancer surgery, patients and surgeons alike can look forward to the promising advancements that such technologies will bring to the medical landscape.